Novozymes Biopharma secures CPhI 2009 innovation award for its albufuse technology
Novozymes Biopharma, part of Novozymes A/S, has claimed the Bronze Innovation Award at the CPhI Worldwide 2009 in Madrid, Spain, for its albumin fusion technology, albufuse. The CPhI Innovation Awards are designed to reward organizations that play a leading role in delivering groundbreaking innovations within the pharmaceutical industry and the company is delighted to add this accolade to its ever-growing collection of industry awards.
Novozymes Biopharma's albufuse technology provides molecular fusion of albumin to protein drug candidates for improved half-life and bioavailability. The simple, single step expression platform is a natural alternative to other technologies such as PEGylation, a chemical conjugation, offering less frequent administration and reduced dosage. In addition, the technology offers customers the benefits of absolutely consistent products, with more simple production and competitive costs enabling long-term supply in large volume quantities.
The CPhI Innovation Awards are established as the showcase for outstanding work in developing research and technology, setting the standards for the pharmaceutical manufacturing industry. The award's judging panel took into consideration a number of factors including effective development of the technology and the key benefits it offers to the pharmaceutical industry.
Other news from the department business & finance
